Exhibit 3.2
SEVENTH AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF
VIVIDION THERAPEUTICS, INC.
Jeffrey S. Hatfield hereby certifies that:
ONE: He is the duly elected and acting Chief Executive Officer of Vividion Therapeutics, Inc., a Delaware corporation.
TWO: The date of filing of said corporation’s original certificate of incorporation with the Delaware Secretary of State was December 24, 2013 under the name Cardinal LS, Inc.
THREE: The Sixth Amended and Restated Certificate of Incorporation of the corporation is hereby amended and restated to read in its entirety as follows:
I.
The name of this corporation is Vividion Therapeutics, Inc. (the “Corporation”).
II.
The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware, 19801, and the name of its registered agent at such address is The Corporation Trust Company.
III.
The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (“DGCL”).
IV.
A. The Corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Corporation is authorized to issue is 310,000,000 shares. 300,000,000 shares shall be Common Stock, each having a par value of $0.001. 10,000,000 shares shall be Preferred Stock, each having a par value of $0.001.
B. The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Corporation (the “Board of Directors”) is hereby expressly authorized to provide for the issue of any or all of the unissued and undesignated shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of
1.